Molecular Partners Announces Participation in Scientific Conferences

Molecular Partners Announces Participation in Scientific Conferences

Written by Customer Service on . Posted in Public Companies.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2022 (GLOBE NEWSWIRE) —  Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its team will participate in the European Hematology Association (EHA) Conference as well as other conferences in June. In addition, Novartis, the global license owner of ensovibep, will present preclinical data from the anti-SARS-CoV-2 program.

Conferences Details:

  • Poster; European Hematology Association (EHA) Conference
    • Title: MP0533, a New Multispecific DARPin CD3 Engager Targeting Three Tumor Associated Antigens, Induces Specific T-cell Activation and AML Tumor Killing in vivo
    • June 9-12, Vienna
  • Poster (Novartis); American Society for Microbiology (ASM Microbe)
    • Title: SARS-CoV-2 Omicron and Multi-variant Neutralization Activity of Ensovibep: A DARPin Therapeutic Candidate For Treatment Of Covid-19
    • June 9-13, Washington, DC
  • Poster; Dissecting Evolution and Heterogeneity of Single Cancer Cells
    • Title: Characterization of Tumor Infiltrating Dendritic Cells at the Single Cell Level
    • June 12-17, Easton, MA

Additional recent presentations:

  • Talks; Antibody Engineering & Therapeutics Europe
    • Title: Ensovibep, a SARS-CoV-2 Multi-Variant Neutralizing DARPin Therapeutic
    • Title: A Triple-targeting DARPin T-cell Engager Approach to Improve Safety and Efficacy for the Treatment of AML
    • June 7-9, 2022, Amsterdam

Presentations will be made available as available, through the Molecular Partners website
        
About Molecular Partners AG 
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter – @MolecularPrtnrs

CONTACT: For further details, please contact:
Seth Lewis
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361

Shai Biran, Ph.D.
shai.biran@molecularpartners.com
Tel: +1 978 254 6286

Thomas Schneckenburger, European IR & Media
thomas.schneckenburger@molecularpartners.com
Tel: +41 79 407 9952

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.